De novo induction of genetically engineered brain tumors in mice using plasmid DNA

Cancer Research

Volumn 69, Issue 2, 2009, Pages 431-439

  Wiesner, Stephen M ^a   Decker, Stacy A ^b   Larson, Jon D ^a,c   Ericson, Katya ^a   Forster, Colleen ^b   Gallardo, Jose L ^b   Long, Chunmei ^b   Demorest, Zachary L ^a   Zamora, Edward A ^b   Low, Walter C ^a,c   SantaCruz, Karen ^b   Largaespada, David A ^a,c   Ohlfest, John R ^a,b,c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID DNA; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; BRAIN TUMOR; CONTROLLED STUDY; GENETIC ENGINEERING; GENETIC TRANSFECTION; GLIOBLASTOMA; HIGH THROUGHPUT SCREENING; IMMUNOCOMPETENCE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; SLEEPING BEAUTY TRANSPOSON; SOUTHERN BLOTTING; TRANSGENIC MOUSE; TRANSPOSON; WESTERN BLOTTING;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; DNA; FEMALE; GENES, REPORTER; GENES, TUMOR SUPPRESSOR; GENETIC ENGINEERING; GLIOMA; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; ONCOGENES; PLASMIDS; POLYETHYLENEIMINE;

EID: 58349109081     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1800     Document Type: Article

References (45)

1. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114:97-109.
2. Davis FG, Kupelian V, Freels S, McCarthy B, Surawicz T. Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro-oncol 2001;3:152-8.
3. Wiesner SM, Freese A, Ohlfest JR. Emerging concepts in glioma biology: implications for clinical protocols and rational treatment strategies. Neurosurg Focus 2005;19:E3.
4. Ren ZP, Olofsson T, Qu M, et al. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors. J Neuropathol Exp Neurol 2007;66:944-54.
5. Cheng Y, Ng HK, Ding M, Zhang SF, Pang JC, Lo KW. Molecular analysis of microdissected de novo glioblastomas and paired astrocytic tumors. J Neuropathol Exp Neurol 1999;58:120-8.
6. Weiss WA, Israel M, Cobbs C, et al. Neuropathology of genetically engineered mice: consensus report and recommendations from an international forum. Oncogene 2002;21:7453-63.
7. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000;26:109-13.
8. Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T. Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res 2005;65:5172-80.
9. Zhu Y , Guignard F, Zhao D, et al. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell 2005;8:119-30.
10. Assanah M, Lochhead R, Ogden A, Bruce J, Goldman J, Canoll P. Glial progenitors in adult white matter are driven to form malignant gliomas by platelet-derived growth factor-expressing retroviruses. J Neurosci 2006;26:6781-90.
11. Uhrbom L, Hesselager G, Nister M, Westermark B. Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 1998;58:5275-9.
12. Holland EC, Hively WP, DePinho RA, Varmus HE. A constitutively active epidermal growth factor receptor cooperates with disruption of G1 cell-cycle arrest pathways to induce glioma-like lesions in mice. Genes Dev 1998;12:3675-85.
13. Holland EC, Varmus HE. Basic fibroblast growth factor induces cell migration and proliferation after gliaspecific gene transfer in mice. Proc Natl Acad Sci U S A 1998;95:1218-23.
14. Uhrbom L, Nerio E, Holland EC. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 2004;10:1257-60.
15. Momota H, Holland EC. Bioluminescence technology for imaging cell proliferation. Curr Opin Biotechnol 2005;16:681-6.
16. Abdallah B, Hassan A, Benoist C, Goula D, Behr JP, Demeneix BA. A powerful nonviral vector for in vivo gene transfer into the adult mammalian brain: polyethylenimine. Hum Gene Ther 1996;7:1947-54.
17. Ohlfest JR, Demorest ZL, Motooka Y, et al. Combinatorial antiangiogenic gene therapy by nonviral gene transfer using the sleeping beauty transposon causes tumor regression and improves survival in mice bearing intracranial human glioblastoma. Mol Ther 2005;12:778-88.
18. Hirko AC, Buethe DD, Meyer EM, Hughes JA. Plasmid delivery in the rat brain. Biosci Rep 2002;22:297-308.
19. Zhang C, Yadava P, Hughes J. Polyethylenimine strategies for plasmid delivery to brain-derived cells. Methods 2004;33:144-50.
20. Ivics Z, Hackett PB, Plasterk RH, Izsvak Z. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell 1997;91:501-10.
21. Ivics Z, Izsvak Z. Transposons for gene therapy! Curr Gene Ther 2006;6:593-607.
22. Carlson CM, Frandsen JL, Kirchhof N, McIvor RS, Largaespada DA. Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouse. Proc Natl Acad Sci U S A 2005;102:17059-64.
23. Dickins RA, Hemann MT, Zilfou JT, et al. Probing tumor phenotypes using stable and regulated synthetic microRNA precursors. Nat Genet 2005;37:1289-95.
24. Geurts AM, Yang Y, Clark KJ, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther 2003;8:108-17.
25. Ohlfest JR, Lobitz PD, Perkinson SG, Largaespada DA. Integration and long-term expression in xenografted human glioblastoma cells using a plasmid-based transposon system. Mol Ther 2004;10:260-8.
26. Wu A, Oh S, Wiesner SM, et al. Persistence of CD133(+) cells in human and mouse glioma cell lines: detailed characterization of gl261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 2008;17:173-84.
27. Wikstrand CJ, McLendon RE, Friedman AH, Bigner DD. Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. Cancer Res 1997;57:4130-40.
28. Panchision DM, Chen HL, Pistollato F, Papini D, Ni HT, Hawley TS. Optimized flow cytometric analysis of CNS tissue reveals novel functional relationships between CD133, CD15 and CD24 expressing cells. Stem Cells 2007;25:1560-70.
29. Wu A, Oh S, Ericson K, et al. Transposon-based interferon γ gene transfer overcomes limitations of episomal plasmid for immunogene therapy of glioblastoma. Cancer Gene Ther 2007;14:550-60.
30. Collier LS, Carlson CM, Ravimohan S, Dupuy AJ, Largaespada DA. Cancer gene discovery in solid tumours using transposon-based somatic mutagenesis in the mouse. Nature 2005;436:272-6.
31. Thomas RK, Nickerson E, Simons JF, et al. Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med 2006;12:852-5.
32. WuA, Oh S, Gharagozlou S, et al. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma. J Immunother (1997) 2007;30:789-97.
33. Ghodsi A, Stein C, Derksen T, Martins I, Anderson RD, Davidson BL. Systemic hyperosmolality improves β-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. Exp Neurol 1999;160:109-16.
34. Lee J, Kotliarova S, Kotliarov Y, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 2006;9:391-403.
35. Gunther HS, Schmidt NO, Phillips HS, et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008;27:2897-909.
36. Fenstermaker RA, Ciesielski MJ. Deletion and tandem duplication of exons 2 - 7 in the epidermal growth factor receptor gene of a human malignant glioma. Oncogene 2000;19:4542-8.
37. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
38. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921.
39. Becher OJ, Hambardzumyan D, Fomchenko EI, et al. Gli activity correlates with tumor grade in platelet-derived growth factor-induced gliomas. Cancer Res 2008;68:2241-9.
40. Doetsch F, Caille I, Lim DA, Garcia-Verdugo JM, Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 1999;97:703-16.
41. Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006;66:3294-302.
42. Pallasch CP, Struss AK, Munnia A, et al. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer 2005;117:456-9.
43. Ueda R, Low KL, Zhu X, et al. Spontaneous immune responses against glioma-associated antigens in a long term survivor with malignant glioma. J Transl Med 2007;5:68.
44. Ohlfest JR, Frandsen JL, Fritz S, et al. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system. Blood 2005;105:2691-8.
45. Pascolo S, Bervas N, Ure JM, Smith AG, Lemonnier FA, PerarnauB. HLA-A2.1-restricted education and cytolytic activity of CD8(+) T lymphocytes from h2 microglobulin (h2m) HLA-A2.1 monochain transgenic H-2Db h2m double knockout mice. J Exp Med 1997;185:2043-51.